Dossier
pubmed
observational
25-oct-2026
Long-term deepening of JAK2V617F molecular response with low-dose ropeginterferon in low-risk polycythaemia vera.
Key claim: Long-term low-dose ropeginterferon deepens JAK2V617F molecular response in patients with low-risk polycythemia vera.
Abstract
No abstract available.
Why this matters
Long-term low-dose ropeginterferon deepens JAK2V617F molecular response in patients with low-risk polycythemia vera.
Source
Link
Briefing card
Long-term deepening of JAK2V617F molecular response with low-dose ropeginterferon in low-risk polycythaemia vera.
Stage: observational
· pubmed
· 25-oct-2026
Long-term low-dose ropeginterferon deepens JAK2V617F molecular response in patients with low-risk polycythemia vera.
Link: /findings/458
Copied
Cross-references (0)
None recorded — doctrine links and citations appear here as scans and citation sweeps find them.
🔎 Pulled in by auto-added search
#7
(pubmed):
"ropeginterferon"[Title/Abstract] AND ("polycythemia vera" OR "myeloproliferative" OR "JAK2")
External: doi:10.1111/bjh.70886
Ask about this finding
Replies are grounded in the abstract and metadata above. The model will
quote directly when possible and say so if a question isn't covered.